If Paxlovid does indeed help lower-risk patients, the size of the treatment benefit for this subgroup is pretty small. So, Peter’s contention that the NEJM dataset was too small to be meaningful for adults age 40-64 misses the point, IMO.
Bolstering the NEJM dataset are the results from PFE’s EPIC-SR trial (#msg-169148071).
News 
Market Data 
Discover 
AI
